Panel Discussion

Time: 5:00 pm
day: Day One


With mRNA- based vaccines now established for certain infectious diseases, it is now important to realise the opportunities of such mRNA- based vaccine therapeutic applications and the surrounding regulatory requirements. From development to commercialization, we will explore aspects of mRNA- based vaccines beyond Sars-COVID-19.

  • What does the future look like for the next generation of mRNA- based vaccines for infectious diseases?
  • Where do we expect innovations to come from and what challenges are ahead of us?
  • What regulatory requirements need to be addressed to overcome the challenges of mRNA- based vaccines 2.0?